The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | The prognostic value of MRD negativity
Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, briefly discusses the importance of measurable residual disease (MRD) in multiple myeloma patients, and the value of MRD negativity in newly diagnosed, transplant-eligible and ineligible patients. Prof. Cavo also mentions the improved prognosis observed in patients who are MRD negative, and further highlights the importance of sustained MRD negativity in patients with high-risk cytogenetics. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
